# Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

> **NCT05265793** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 45 (estimated)

## Conditions studied

- PD-1 Immunotherapy
- VEGFR-TKI
- Sarcomatoid Carcinoma
- Carcinosarcoma

## Interventions

- **DRUG:** Camrelizumab Combined With Apatinib

## Key facts

- **NCT ID:** NCT05265793
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-21
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2022-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05265793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05265793, "Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05265793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*